AstraZeneca Donates $225,000 to Support Heart Disease Research

Contribution Made to the University of Ottawa Heart Institute at 22(nd) Annual 
Telethon 
MISSISSAUGA, ON, March 8, 2013 /CNW/ - AstraZeneca Canada is pleased to 
announce a $225,000 donation to the University of Ottawa Heart Institute 
(UOHI). Presented by AstraZeneca Canada President, Elaine Campbell, during 
the 22(nd) annual UOHI Telethon on March 3, 2012, the donation will support 
the institute's world leading medical research program and cardiovascular 
patient education initiatives. 
In addition, to encourage the Ottawa community to call in with a pledge, 
AstraZeneca sponsored the Three-Minute Challenge, matching all incoming phone 
pledges over a three-minute period, up to $5,000. AstraZeneca has 
participated in the Three-Minute Challenge in each of the last 15 years. 
"Across this country, thousands of Canadians are living with heart disease - 
the second leading cause of death," explains Elaine Campbell. "This is why 
we remain committed to supporting cardiovascular research through centers of 
excellence such as the Ottawa Heart Institute - ultimately advancing our 
understanding of cardiovascular disease and prevention, with a collective goal 
to reduce prevalence of heart disease, and its impact on patients and their 
families." 
Canada's largest and foremost cardiovascular health centre, the University of 
Ottawa Heart Institute is dedicated to understanding, treating, and preventing 
heart disease. Dr. Michel Le May, a cardiologist at the Ottawa Heart 
Institute, developed a STEMI program that has established protocols to ensure 
that heart attack patients in the Ottawa region receive the best care as 
quickly as possible. Through in-depth training of paramedics, patients who 
receive a STEMI diagnosis in the ambulance are able to be transported directly 
to the Heart Institute for treatment. As a result of the STEMI program, STEMI 
deaths in the Ottawa region have been reduced by 50 per cent.(1) The program 
has been carried out in communities across Canada. 
Although significant treatment advances have been made in recent years, heart 
disease remains Canada's second leading cause of death and a significant 
burden on our healthcare system.(2) Nearly five per cent of Canadians over 
the age of 12 report living with heart disease.(3) Acute Coronary Syndrome 
(ACS) events (heart attacks or chest pain), in particular, result in 100,000 
hospitalizations annually — that's one Canadian admitted to hospital every 
five minutes.(4) It is estimated that ACS events alone add $3.4 billion each 
year in direct healthcare expenditures and economic losses to Canada's already 
strained health-care system.(5) 
About AstraZeneca Canada
AstraZeneca is a global, innovation-driven biopharmaceutical business with a 
primary focus on the discovery, development and commercialization of 
prescription medicines for gastrointestinal, cardiovascular, neuroscience, 
respiratory and inflammation, oncology and infectious disease. AstraZeneca 
operates in over 100 countries and its innovative medicines are used by 
millions of patients worldwide. AstraZeneca's Canadian headquarters are 
located in Mississauga, Ontario. For more information, please visit the 
company's website at www.astrazeneca.ca. 
About the University of Ottawa Heart Institute
The University of Ottawa Heart Institute (UOHI) is Canada's largest and 
foremost cardiovascular health centre dedicated to understanding, treating and 
preventing heart disease. UOHI delivers high-tech care with a personal touch, 
shapes the way cardiovascular medicine is practiced and revolutionizes cardiac 
treatment and understanding. It builds knowledge through research and 
translates discoveries into advanced care. UOHI serves the local, national and 
international community, and is pioneering a new era in heart health. For more 
information visit: www.ottawaheart.ca 
REFERENCES: 
_______________________________________________
(1) University of Ottawa Heart Institute. Website. Heart Attack: 
http://www.ottawaheart.ca/heart_disease/heart-attack.htm
(2) Statistics Canada.Morality, Summary List of Causes 2008. Released 
October 18, 2011
(3) Public Health Agency of Canada. Tracking Heart Disease and Stroke in 
Canada. Released June 2009
(4) Charles River Associates' Life Sciences Practice. The burden of acute 
coronary syndrome: The second leading cause of death in Canada. Study 
commissioned by AstraZeneca.
(5) Charles River Associates' Life Sciences Practice. The burden of acute 
coronary syndrome: The second leading cause of death in Canada. Study 
commissioned by AstraZeneca. 
Adam Sanders Edelman Tel: 416-850-0241 adam.sanders@edelman.com 
SOURCE: AstraZeneca Canada Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/March2013/08/c3458.html 
CO: AstraZeneca Canada Inc.
ST: Ontario
NI: HEA HEA  
-0- Mar/08/2013 22:46 GMT